Zacks1d agoneutral
VRTX's Q2 Earnings Lag Estimates, Revenues Top, 2026 Sales View RaisedVertex's Q2 earnings miss estimates, but revenues beat. It lifts its 2026 sales outlook, and sees growing contributions from newer products.
News
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
530last 24h
2509last 7d
478● bullish (7d)
254● bearish (7d)
197publishers
Zacks1d agoneutral
CRISPR Therapeutics' Q2 Earnings & Revenues Surpass EstimatesCRSP reports a narrower-than-expected Q2 loss. Revenues beat estimates as Casgevy sales surge across global markets and clinical programs advance.
Zacks1d agobullish
CRISPR Therapeutics AG (CRSP) Reports Q2 Loss, Tops Revenue EstimatesCRISPR Therapeutics (CRSP) delivered earnings and revenue surprises of +14.55% and +37.28%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks8d agoneutral
Earnings Preview: Ultragenyx (RARE) Q2 Earnings Expected to DeclineUltragenyx (RARE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks9d agobullish
CRISPR Therapeutics AG (CRSP) Expected to Beat Earnings Estimates: Can the Stock Move Higher?CRISPR Therapeutics (CRSP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks63d agoneutral
Why Is CRISPR Therapeutics (CRSP) Down 0.7% Since Last Earnings Report?CRISPR Therapeutics (CRSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Insider Monkey74d agoneutral
CRISPR Therapeutics AG (CRSP) Reports Q1 2026 ResultsCRISPR Therapeutics AG (NASDAQ:CRSP) is one of the 10 Best ARK Stocks to Buy Right Now. On May 4, CRISPR Therapeutics AG (NASDAQ:CRSP) reported its first quarter 2026 results and advanced its pipeline and commercial launch. The company reported a net loss of $122.9 million for Q1 2026, lower than $136.0 million a year earlier. […]
Zacks89d agoneutral
VRTX's Alyftrek, Journavx & Casgevy See Strong Momentum in Q1 EarningsVertex's new drugs are gaining momentum as Alyftrek tops $1 billion in sales and Journavx prescriptions accelerate.
Zacks92d agobullish
VRTX's Q1 Earnings Beat Estimates, New Products Aid Sales GrowthVertex tops Q1 estimates as revenues climb 8% on strong CF drug demand and new product gains. Its pipeline has advanced and its 2026 guidance reaffirmed.
Zacks92d agoneutral
CRISPR Therapeutics AG (CRSP) Reports Q1 Loss, Lags Revenue EstimatesCRISPR Therapeutics (CRSP) delivered earnings and revenue surprises of -12.39% and -82.62%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Simply Wall St.97d agoneutral
Why CRISPR Therapeutics (CRSP) Is Down 10.1% After Casgevy’s Strong Early Launch Metrics And Earnings HopesIn late April 2026, analysts highlighted expectations for higher year-over-year earnings and revenue at CRISPR Therapeutics ahead of its March-quarter report, alongside strong launch metrics for Casgevy, the gene therapy it co-commercializes with Vertex Pharmaceuticals. An interesting angle for investors is how Casgevy’s early commercial uptake and growing treated-patient base may influence perceptions of CRISPR Therapeutics’ broader gene-editing platform and revenue potential. With the...
Zacks98d agobullish
Mirum Pharmaceuticals, Inc. (MIRM) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 ReleaseMirum Pharmaceuticals (MIRM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.